Clinical trial
Treatment of Early Aggressive Rheumatoid Arthritis (TEAR)
NCT00259610 · University of Alabama at Birmingham, Other · Completed
Key facts
| NCT number | NCT00259610 |
|---|---|
| Title | Treatment of Early Aggressive Rheumatoid Arthritis (TEAR) |
| Official title | Treatment of Early Aggressive Rheumatoid Arthritis (TEAR) |
| Acronym | TEAR |
| Lead sponsor | University of Alabama at Birmingham, Other |
| Collaborators | Amgen Industry Barr Laboratories Pfizer |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Rheumatoid Arthritis |
| Intervention type | Drug |
| Interventions | methotrexate, sulfasalazine, hydroxychloroquine, etanercept |
| Enrollment | 755 |
| Start date | May 1, 2004 |
| Primary completion | Jun 1, 2009 |
| Completion | Jun 1, 2009 |
| First posted | Nov 29, 2005 |
| Last update posted | Jul 17, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: